Precision epilepsy testing

Improving outcomes with inclusive, individualized testing

Affecting 1%–2% of individuals worldwide,^1,2 epilepsy is one of the most common neurological disorders globally. The condition has numerous causes, among them immune-mediated, genetic, metabolic, vascular, and infectious, and can be difficult to accurately diagnose. Epilepsy can also be challenging to treat, with at least 30% of affected patients having drug-resistant epilepsy (DRE).³

Precision epilepsy testing is a holistic approach to diagnostic care that overcomes the complexities of diagnosis and treatment resistance by personalizing diagnosis, medication selection, and dosing. Coupling diagnostic tests with pharmacogenomic (PGx) and therapeutic drug monitoring (TDM) assays, precision epilepsy testing can help pinpoint the underlying etiology, optimize treatment selection by establishing a patient’s genetic profile, and preserve treatment efficacy by analyzing medication concentrations.  

Mayo Clinic Laboratories’ precision epilepsy offering encompasses the full spectrum of tests needed to identify the correct cause and individualize treatment. Designed to align with national practice guidelines and backed by clinical data, our integrated tests provide rapid answers that support seizure control, reduce hospitalizations, and restore a patient’s quality of life.